<DOC>
	<DOCNO>NCT02725437</DOCNO>
	<brief_summary>The first-in-Japanese study B5091010 design evaluate safety , tolerability , immunogenicity 2 antigen dose level C difficile vaccine administer one two 3-dose regimen healthy Japanese adult age 65 85 year .</brief_summary>
	<brief_title>Clostridium Difficile Vaccine Safety , Tolerability , Immunogenicity Study Japanese Adults</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female adult 2 . Aged 65 85 year 1 . Proven suspect prior episode Clostridium difficile associate diarrhea 2 . Unstable chronic medical condition 3 . Disease require significant change therapy hospitalization worsen disease within 8 week receipt study vaccine 4 . Serious chronic medical disorder 5 . Bleeding diathesis condition associate prolonged bleeding time may contraindicate intramuscular injection 6 . Any contraindication vaccination vaccine component , include previous anaphylactic reaction vaccine vaccinerelated component 7 . Subjects congenital acquire immunodeficiency disorder 8 . Subjects rheumatologic disorder illness require chronic treatment know immunosuppressant medication 9 . Active treat leukemia lymphoma bone marrow disorder 10 . Residence nursing home longterm care facility , requirement semiskilled nursing care assist live 11 . Abnormality screen hematology and/or blood chemistry laboratory value</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>